ArticleInflammopharmacology2026
Stigmasterol attenuates cuprizone-induced neuroinflammation and demyelination in rats through modulation of inflammatory mediators and oxidative stress.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMultiple sclerosis is a neuroinflammatory and demyelinating condition of brain with limited therapeutic options, many of which are associated with high treatment costs and adverse effects, In this research work, the neuroprotective potential of stigmasterol was investigated in a rat model of cuprizone-induced neuroinflammation and demyelination. MATERIALS AND
methodsA total of 36 Wistar rats (150-200 g) of both sexes were divided into 6 groups (n = 6) in random manner. Neuroinflammation and demyelination were induced by feeding animals a 0.3% cuprizone-containing diet for 5 weeks. Stigmasterol (100, 200, or 400 mg/kg/day) or dimethyl fumarate (15 mg/kg/day) was then administered orally for 3 weeks while cuprizone administration continued. After behavioral analysis, oxidative stress biomarkers, neurotransmitter levels, myelin-basic protein concentration by ELISA, mRNA expression of myelin basic protein and inflammatory cytokines, and histopathological alternations were evaluated.
resultsCuprizone administration pointedly increased oxidative stress, impaired behavioral performances, induced marked histopathological alterations, reduced mRNA expression of MBP and the anti-inflammatory cytokines, and elevated expression of inflammatory cytokines. Compared with cuprizone group, stigmasterol treatment prominently improved cognitive and locomotor performance (P < 0.001), restored antioxidant status (P < 0.001), upregulated the mRNA expression of IL-4, IL-10 and MBP, downregulated expression of IL-1β, TNF-α and IL-6, and increased both neurotransmitter concentrations (P < 0.001) and MBP concentrations in a dose-dependent manner. The effects of dimethyl fumarate were comparable to those observed with the highest dose of stigmasterol.
conclusionStigmasterol alleviated cuprizone-induced neuroinflammation, demyelination, oxidative stress and behavioral deficits while restoring MBP expression and modulating inflammatory cytokines expression. These results suggest that stigmasterol possesses neuroprotective and anti-inflammatory properties and warrants further investigation as an effective therapeutic candidate for demyelinating and neuroinflammatory disorders.
Indexed as
Identifiers
42832007What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.